MX2018014357A - Uso de inhibidores de la via del complemento para tratar enfermedades oculares. - Google Patents
Uso de inhibidores de la via del complemento para tratar enfermedades oculares.Info
- Publication number
- MX2018014357A MX2018014357A MX2018014357A MX2018014357A MX2018014357A MX 2018014357 A MX2018014357 A MX 2018014357A MX 2018014357 A MX2018014357 A MX 2018014357A MX 2018014357 A MX2018014357 A MX 2018014357A MX 2018014357 A MX2018014357 A MX 2018014357A
- Authority
- MX
- Mexico
- Prior art keywords
- factor
- ocular diseases
- complement pathway
- pathway inhibitors
- treat ocular
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Marine Sciences & Fisheries (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
Abstract
La presente invención se refiere al tratamiento de enfermedades y condiciones oculares mediante la administración de un inhibidor de la vía del complemento, particularmente un inhibidor de la vía alternativa. Las enfermedades oculares incluyen la degeneración macular relacionada con la edad, retinopatía diabética, y angiogénesis ocular. Una modalidad comprende la administración de un anticuerpo anti-Factor D en la forma de un anticuerpo completo, un fragmento de Fab o un anticuerpo de dominio único. Otros inhibidores del componente del complemento que pueden ser útiles en el presente método incluyen el Factor H o inhibidores que bloquean la acción de la properdina, factor B, factor Ba, factor Bb, C2, C2a, C3a, C5, C5a, C5b, C6, C7, C8, C9 o C5b-9.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73376305P | 2005-11-04 | 2005-11-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018014357A true MX2018014357A (es) | 2020-09-14 |
Family
ID=38023865
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011003503A MX337061B (es) | 2005-11-04 | 2006-11-04 | Uso de inhibidores de la via del complemento para tratar enfermedades oculares. |
MX2016001813A MX360959B (es) | 2005-11-04 | 2006-11-04 | Uso de inhibidores de la vía del complemento para tratar enfermedades oculares. |
MX2018014357A MX2018014357A (es) | 2005-11-04 | 2008-04-30 | Uso de inhibidores de la via del complemento para tratar enfermedades oculares. |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011003503A MX337061B (es) | 2005-11-04 | 2006-11-04 | Uso de inhibidores de la via del complemento para tratar enfermedades oculares. |
MX2016001813A MX360959B (es) | 2005-11-04 | 2006-11-04 | Uso de inhibidores de la vía del complemento para tratar enfermedades oculares. |
Country Status (29)
Country | Link |
---|---|
US (3) | US8753625B2 (es) |
EP (4) | EP2500030B2 (es) |
JP (7) | JP2009514888A (es) |
KR (6) | KR20170002684A (es) |
CN (2) | CN107929731A (es) |
AU (1) | AU2006311803C1 (es) |
BR (1) | BRPI0619657A2 (es) |
CA (2) | CA2624393C (es) |
CR (1) | CR10041A (es) |
DK (1) | DK2500030T4 (es) |
EC (1) | ECSP088500A (es) |
ES (1) | ES2551202T5 (es) |
HK (2) | HK1175718A1 (es) |
HU (1) | HUE026423T2 (es) |
IL (3) | IL190547A (es) |
MA (1) | MA29976B1 (es) |
MX (3) | MX337061B (es) |
MY (1) | MY151064A (es) |
NO (1) | NO20082483L (es) |
NZ (2) | NZ567483A (es) |
PH (1) | PH12013501270B1 (es) |
PL (1) | PL2500030T5 (es) |
PT (1) | PT2500030E (es) |
RU (2) | RU2417099C2 (es) |
SG (1) | SG10201804008UA (es) |
SI (1) | SI2500030T2 (es) |
UA (1) | UA99591C2 (es) |
WO (1) | WO2007056227A2 (es) |
ZA (2) | ZA200803659B (es) |
Families Citing this family (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1713503T3 (da) | 2004-02-10 | 2013-11-04 | Univ Colorado Regents | Hæmning af faktor b, den alternative komplemenpathway og dertil relaterede fremgangsmåde |
US8088587B2 (en) | 2005-03-04 | 2012-01-03 | Vanderbilt University | Genetic variants increase the risk of age-related macular degeneration |
JP5707024B2 (ja) | 2005-05-26 | 2015-04-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイトTHE REGENTS OF THE UNIVERSITY OF COLORADO,a body corporate | 外傷性脳損傷、脊髄損傷および関連状態を治療するために補体副経路を阻害する作用剤 |
US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
KR20170002684A (ko) | 2005-11-04 | 2017-01-06 | 제넨테크, 인크. | 안질환 치료를 위한 보체 경로 억제제의 용도 |
PL2044111T3 (pl) | 2006-06-21 | 2015-02-27 | Musc Found For Res Dev | Celowanie czynnika H dopełniacza do leczenia chorób |
US8703136B2 (en) | 2006-10-10 | 2014-04-22 | Regenesance B.V. | Complement inhibition for improved nerve regeneration |
PE20121034A1 (es) * | 2006-11-02 | 2012-08-25 | Genentech Inc | Anticuerpos anti-factor d humanizados |
AU2008251943B2 (en) | 2007-03-14 | 2013-09-05 | Alexion Pharmaceuticals, Inc. | Humaneered anti-factor B antibody |
CA2680760A1 (en) * | 2007-03-22 | 2008-09-25 | Novartis Ag | C5 antigens and uses thereof |
AR066660A1 (es) * | 2007-05-23 | 2009-09-02 | Genentech Inc | Prevencion y tratamiento de condiciones del ojo asociadas con su complemento |
EP2195024B1 (en) * | 2007-08-27 | 2016-10-05 | NovelMed Therapeutics, Inc. | Method of inhibiting complement activation with factor bb specific antibodies |
US10131706B2 (en) | 2007-08-27 | 2018-11-20 | Novelmed Therapeutics, Inc. | Anti-factor Bb antibodies |
GB0718737D0 (en) * | 2007-09-25 | 2007-11-07 | Glaxo Group Ltd | Antibodies |
AU2008323939A1 (en) * | 2007-11-08 | 2009-05-14 | Genentech, Inc. | Anti-factor B antibodies and their uses |
US20110182910A1 (en) * | 2008-03-06 | 2011-07-28 | Medof M Edward | Method of treating t cell mediated disorders |
AU2013200637B2 (en) * | 2008-04-28 | 2015-07-16 | Genentech, Inc. | Humanized anti-Factor D antibodies and uses thereof |
CR20170001A (es) * | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
ES2566008T3 (es) * | 2008-07-10 | 2016-04-08 | Regenesance B.V. | Antagonistas de complementos y usos de los mismos |
EP2815766B1 (en) | 2008-08-05 | 2017-07-05 | Novartis AG | Compositions and methods for antibodies targeting complement protein C5 |
US8092013B2 (en) * | 2008-10-28 | 2012-01-10 | Johnson & Johnson Vision Care, Inc. | Apparatus and method for activation of components of an energized ophthalmic lens |
EP2391419B1 (en) | 2009-01-29 | 2019-06-12 | ForSight Vision4, Inc. | Posterior segment drug delivery |
US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
EP2453906A4 (en) | 2009-07-02 | 2014-01-15 | Musc Found For Res Dev | METHOD FOR STIMULATING THE LIVER REGENERATION |
CN102958535A (zh) | 2009-11-05 | 2013-03-06 | 亚力史剑桥公司 | 阵发性夜间血红蛋白尿、溶血性贫血和涉及血管内和血管外溶血的疾病状态的治疗 |
US20130011857A1 (en) | 2010-02-12 | 2013-01-10 | Cemm Forschungszentrum Fur Molekulare Medizin Gmbh | Complement factor h for oxidative stress disease conditions |
JP5828195B2 (ja) | 2010-03-11 | 2015-12-02 | ユニバーシティ オブ ルイスビル リサーチ ファンデーション,インコーポレイテッドUniversity Of Louisville Research Foundation,Inc. | 妊娠損失リスクを予測する方法および妊娠損失リスクを低下させる方法 |
US9011852B2 (en) | 2010-04-30 | 2015-04-21 | Alexion Pharmaceuticals, Inc. | Anti-C5a antibodies |
CN103038252A (zh) | 2010-05-14 | 2013-04-10 | 科罗拉多大学董事会,法人团体 | 改良的补体受体2(cr2)靶向群 |
WO2011163394A2 (en) | 2010-06-22 | 2011-12-29 | Apellis Pharmaceuticals, Inc. | Compstatin analogs for treatment of neuropathic pain |
AU2011270959A1 (en) | 2010-06-22 | 2013-01-10 | Musc Foundation For Research Development | Antibodies to the C3d fragment of complement component 3 |
PT2600812T (pt) * | 2010-08-05 | 2021-11-09 | Forsight Vision4 Inc | Aparelho para tratar um olho |
US9370444B2 (en) | 2010-10-12 | 2016-06-21 | Emmett T. Cunningham, JR. | Subconjunctival conformer device and uses thereof |
US8915877B2 (en) | 2010-10-12 | 2014-12-23 | Emmett T. Cunningham, JR. | Glaucoma drainage device and uses thereof |
KR20130130732A (ko) | 2010-11-01 | 2013-12-02 | 제넨테크, 인크. | 다유전자 스코어를 이용한 진행성 노인성 황반 변성으로의 진행 예측 |
EP2640360A2 (en) | 2010-11-19 | 2013-09-25 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
CN103261893A (zh) * | 2010-11-29 | 2013-08-21 | 诺沃姆德治疗公司 | 用于诊断组织损害的新抗体 |
BR112013028271B1 (pt) | 2011-05-05 | 2020-11-24 | Wellstat Immuno Therapeutics, Llc | Polipeptideo, acido nucleico, vetor viral, preparação farmaceutica, bem como uso dos mesmos no tratamento de doenqa mediada por complemento |
CN107050422B (zh) * | 2011-05-11 | 2021-11-09 | 阿佩利斯制药公司 | 细胞反应性的、长效的或靶向的坎普他汀类似物及其用途 |
US10588879B2 (en) * | 2011-08-01 | 2020-03-17 | Aurin Biotech Inc. | Treatment of age-related macular degeneration |
EP2739252A4 (en) | 2011-08-05 | 2015-08-12 | Forsight Vision4 Inc | SMALL MOLECULE ADMINISTRATION USING AN IMPLANTABLE THERAPEUTIC DEVICE |
AU2012356170B2 (en) | 2011-12-21 | 2016-06-16 | Novartis Ag | Compositions and methods for antibodies targeting Factor P |
WO2013126006A1 (en) * | 2012-02-20 | 2013-08-29 | Swedish Orphan Biovitrum Ab (Publ) | Polypeptides binding to human complement c5 |
WO2013142362A1 (en) * | 2012-03-19 | 2013-09-26 | The Trustees Of The University Of Pennsylvania | Regulator of complement activation and uses thereof |
FR2988298A1 (fr) * | 2012-03-23 | 2013-09-27 | Lfb Biotechnologies | Facteur h pour son utilisation comme molecule antioxydante |
WO2013152020A1 (en) | 2012-04-03 | 2013-10-10 | Novelmed Therapeutics, Inc. | Humanized and chimeric anti-factor bb antibodies and uses thereof |
US9056874B2 (en) | 2012-05-04 | 2015-06-16 | Novartis Ag | Complement pathway modulators and uses thereof |
EP2855529A4 (en) | 2012-05-24 | 2015-12-09 | Alexion Pharma Inc | HUMANIZED ANTI-FACTOR B ANTIBODIES |
CA2877526A1 (en) * | 2012-06-20 | 2013-12-27 | Novartis Ag | Complement pathway modulators and uses thereof |
KR102073312B1 (ko) * | 2012-06-27 | 2020-02-05 | 엘지전자 주식회사 | 당뇨망막병증 진단용 마커 및 이의 용도 |
CN102743371A (zh) * | 2012-07-26 | 2012-10-24 | 山东省眼科研究所 | 一种治疗视网膜新生血管性疾病的药物 |
AU2013302441B2 (en) | 2012-08-17 | 2018-05-10 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for detecting complement activation |
US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
US9926366B2 (en) | 2012-10-04 | 2018-03-27 | Novelmed Therapeutics, Inc. | Methods of treating a hemolytic disorder comprising administering anti-properdin antibodies |
SI3660033T1 (sl) | 2012-11-15 | 2021-09-30 | Apellis Pharmaceuticals, Inc. | Analogi kompstatina z dolgotrajnim delovanjem in sorodni sestavki in postopki |
EP2975055A4 (en) * | 2013-01-31 | 2016-11-02 | Univ Seoul Nat R & Db Found | C5 ANTIBODIES AND METHOD FOR PREVENTING AND TREATING COMPLEMENT-MEDIATED ILLNESSES |
WO2014152959A1 (en) | 2013-03-14 | 2014-09-25 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
WO2014143638A1 (en) | 2013-03-14 | 2014-09-18 | Novartis Ag | 2-(1h-indol-4-ylmethyl)-3h-imidazo[4,5-b]pyridine-6-carbonitrile derivatives as complement factor b inhibitors useful for the treatment of ophthalmic diseases |
WO2014152391A1 (en) | 2013-03-15 | 2014-09-25 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
EP2978393B1 (en) | 2013-03-28 | 2023-12-27 | ForSight Vision4, Inc. | Ophthalmic implant for delivering therapeutic substances |
WO2014170786A1 (en) | 2013-04-17 | 2014-10-23 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
AU2014286996A1 (en) | 2013-07-12 | 2016-01-07 | Iveric Bio, Inc. | Methods for treating or preventing ophthalmological conditions |
CN107318267B (zh) * | 2013-08-12 | 2021-08-17 | 豪夫迈·罗氏有限公司 | 用于治疗补体相关的病症的组合物和方法 |
WO2015054298A1 (en) * | 2013-10-07 | 2015-04-16 | Massachusetts Eye And Ear Infirmary | Methods of preventing or reducing photoreceptor cell death |
US9676728B2 (en) | 2013-10-30 | 2017-06-13 | Novartis Ag | 2-benzyl-benzimidazole complement factor B inhibitors and uses thereof |
WO2015099838A2 (en) * | 2013-12-24 | 2015-07-02 | Novelmed Therapeutics, Inc. | Compositions and methods of treating ocular diseases |
EP3110845A1 (en) | 2014-02-27 | 2017-01-04 | Allergan, Inc. | Complement factor bb antibodies |
EA201692109A1 (ru) | 2014-05-01 | 2017-03-31 | Дженентек, Инк. | Варианты антител к фактору d и их применение |
EP4223317A3 (en) | 2014-06-12 | 2023-09-27 | RA Pharmaceuticals, Inc. | Modulation of complement activity |
EP3177289A4 (en) | 2014-08-08 | 2018-03-21 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
CN107074939B (zh) * | 2014-08-20 | 2021-09-07 | 桑昆血液供给基金会 | H因子增强抗体及其用途 |
EA201791029A1 (ru) | 2014-11-10 | 2017-12-29 | Дженентек, Инк. | Антитела против интерлейкина-33 и их применение |
EP3988110A1 (en) | 2015-01-28 | 2022-04-27 | RA Pharmaceuticals, Inc. | Modulators of complement activity |
JP7261583B2 (ja) | 2015-09-24 | 2023-04-20 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 補体媒介性疾患を処置するための組成物及び方法 |
RU2770099C2 (ru) | 2015-10-07 | 2022-04-14 | Апеллис Фармасьютикалс, Инк. | Схемы введения |
CN108289951A (zh) | 2015-10-30 | 2018-07-17 | 豪夫迈·罗氏有限公司 | 抗-因子d抗体和缀合物 |
PL3368682T3 (pl) | 2015-10-30 | 2020-05-18 | F. Hoffmann-La Roche Ag | Sposoby pomiaru aktywności czynnika D i siły działania inhibitorów czynnika D |
EP3368090A1 (en) | 2015-10-30 | 2018-09-05 | H. Hoffnabb-La Roche Ag | Anti-factor d antibody variant conjugates and uses thereof |
MX2018007352A (es) | 2015-12-16 | 2019-05-16 | Ra Pharmaceuticals Inc | Moduladores de la actividad del complemento. |
JP7199966B2 (ja) * | 2015-12-23 | 2023-01-06 | ソルボンヌ ウニベルシテ | CD11b/CD18に対するCFHの結合を阻害する薬剤、およびその使用 |
EP3405577B8 (en) | 2016-01-20 | 2023-02-15 | 396419 B.C. Ltd. | Compositions and methods for inhibiting factor d |
CR20180529A (es) | 2016-04-04 | 2019-03-21 | Bioverativ Usa Inc | Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada |
IL309975A (en) | 2016-06-14 | 2024-03-01 | Regeneron Pharma | Antibodies against C5 and their uses |
BR112019011053A2 (pt) | 2016-12-07 | 2019-10-15 | Ra Pharmaceuticals Inc | moduladores da atividade do complemento |
WO2018136827A1 (en) | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Stem-loop compositions and methods for inhibiting factor d |
CN118184777A (zh) * | 2017-01-30 | 2024-06-14 | 亚力兄制药公司 | 单价抗备解素抗体及抗体片段 |
JP2020507581A (ja) | 2017-02-10 | 2020-03-12 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 抗d因子抗体及びその使用 |
US11040107B2 (en) | 2017-04-07 | 2021-06-22 | Apellis Pharmaceuticals, Inc. | Dosing regimens and related compositions and methods |
WO2018191548A2 (en) | 2017-04-14 | 2018-10-18 | Kodiak Sciences Inc. | Complement factor d antagonist antibodies and conjugates thereof |
AU2018301412A1 (en) | 2017-07-11 | 2020-01-30 | Alexion Pharmaceuticals, Inc. | Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereof |
CN111527105A (zh) * | 2017-10-11 | 2020-08-11 | 美国比奥维拉迪维股份有限公司 | 诱导补体活性的方法 |
CN111683672A (zh) | 2017-12-04 | 2020-09-18 | Ra制药公司 | 补体活性调节剂 |
CN111630065A (zh) | 2017-12-13 | 2020-09-04 | 瑞泽恩制药公司 | 抗c5抗体组合及其用途 |
GB201800620D0 (en) | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
KR20200138290A (ko) | 2018-04-03 | 2020-12-09 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | C3-결합제 및 이의 사용 방법 |
WO2019215330A1 (en) * | 2018-05-10 | 2019-11-14 | The University Of Manchester | Methods for assessing macular degeneration |
EP3586865A1 (en) * | 2018-06-21 | 2020-01-01 | Charité - Universitätsmedizin Berlin | Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis |
CN113543796A (zh) | 2019-03-08 | 2021-10-22 | Ra制药公司 | 齐鲁考普作为深层组织穿透性c5抑制剂 |
CA3134614A1 (en) | 2019-03-29 | 2020-10-08 | Ra Pharmaceuticals, Inc. | Complement modulators and related methods |
BR112021017820A2 (pt) | 2019-04-24 | 2022-02-08 | Ra Pharmaceuticals Inc | Composições e métodos para modulação da atividade de complemento |
AR122286A1 (es) | 2019-07-17 | 2022-08-31 | Gemini Therapeutics Sub Inc | Anticuerpos potenciadores del factor h y usos de estos |
KR102428619B1 (ko) | 2019-09-25 | 2022-08-04 | 대구가톨릭대학교산학협력단 | 망막병증 치료용 약물 방출 콘택트렌즈 및 이의 제조방법 |
IL296256A (en) | 2020-03-13 | 2022-11-01 | Genentech Inc | Antibodies against interleukin-33 and uses thereof |
CA3173325A1 (en) | 2020-04-20 | 2021-10-28 | Graham Parry | Humanized anti-complement factor bb antibodies and uses thereof |
CN114686481B (zh) * | 2020-12-31 | 2023-08-15 | 北京键凯科技股份有限公司 | 一种抑制cfd表达的干扰rna及其制备方法和应用 |
WO2024006902A2 (en) * | 2022-06-30 | 2024-01-04 | Iveric Bio, Inc. | Sustained release silica hydrogel composites for treating ophthalmological conditions and methods of using same |
Family Cites Families (144)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5022A (en) * | 1847-03-20 | Alfred stillman | ||
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
JP2532858B2 (ja) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | 形質転換したミエロ―マ細胞系 |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5256642A (en) | 1988-04-01 | 1993-10-26 | The Johns Hopkins University | Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof |
DE68921982D1 (de) | 1988-06-14 | 1995-05-04 | Cetus Oncology Corp | Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus. |
US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
ES2052027T5 (es) | 1988-11-11 | 2005-04-16 | Medical Research Council | Clonacion de secuencias de dominio variable de inmunoglobulina. |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
AU641673B2 (en) | 1989-06-29 | 1993-09-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
AU633698B2 (en) | 1990-01-12 | 1993-02-04 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
JP3319594B2 (ja) | 1990-03-20 | 2002-09-03 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | 定常領域の代わりに受容体結合性リガンドを有するキメラ抗体 |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
JPH07500961A (ja) | 1990-10-01 | 1995-02-02 | ユニバーシティ オブ コネチカット | 細胞による選択的内在化を目的としたウイルス及び細胞の標的設定 |
ES2129029T5 (es) | 1990-10-05 | 2005-10-16 | Celldex Therapeutics, Inc. | Inmunoestimulacion dirigida con reactivos biespecificos. |
WO1992008802A1 (en) | 1990-10-29 | 1992-05-29 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
ATE218889T1 (de) | 1990-11-09 | 2002-06-15 | Stephen D Gillies | Cytokine immunokonjugate |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
AP257A (en) | 1991-04-26 | 1993-06-03 | Surface Active Ltd | A method of releasing an antigen from an antibody and methods for their use in diagnosis and therapy. |
AU668870B2 (en) | 1991-05-14 | 1996-05-23 | Targetech, Inc | Targeted delivery of genes encoding immunogenic proteins |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
AU2160992A (en) | 1991-06-05 | 1993-01-12 | Board Of Regents Acting For And On Behalf Of The University Of Michigan, The | Targeted delivery of genes encoding secretory proteins |
EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
ATE275198T1 (de) | 1991-12-02 | 2004-09-15 | Medical Res Council | Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken. |
AU3434393A (en) | 1992-01-17 | 1993-08-03 | Regents Of The University Of Michigan, The | Targeted virus |
AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
ES2193143T3 (es) | 1992-03-05 | 2003-11-01 | Univ Texas | Uso de inmunoconjugados para la diagnosis y/o terapia de tumores vascularizaos. |
CA2133411A1 (en) | 1992-04-03 | 1993-10-14 | Alexander T. YOUNG | Gene therapy using targeted viral vectors |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
RU2135720C1 (ru) | 1992-06-09 | 1999-08-27 | Хоппе Аг | Запирающее устройство |
US5456909A (en) | 1992-08-07 | 1995-10-10 | T Cell Sciences, Inc. | Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo |
JPH08501085A (ja) | 1992-08-26 | 1996-02-06 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 抗腫瘍剤としてのサイトカインip−10の利用 |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
JP3789930B2 (ja) | 1992-10-09 | 2006-06-28 | アドバンスド ティシュー サイエンシズ,インコーポレーテッド | 肝予備細胞 |
AU680459B2 (en) | 1992-12-03 | 1997-07-31 | Genzyme Corporation | Gene therapy for cystic fibrosis |
US5861156A (en) | 1993-01-08 | 1999-01-19 | Creative Biomolecules | Methods of delivering agents to target cells |
AU6796094A (en) | 1993-04-29 | 1994-11-21 | Raymond Hamers | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae) |
US5856300A (en) | 1994-05-12 | 1999-01-05 | T Cell Sciences, Inc. | Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions |
US5679546A (en) | 1993-09-24 | 1997-10-21 | Cytomed, Inc. | Chimeric proteins which block complement activation |
US5627264A (en) | 1994-03-03 | 1997-05-06 | Alexion Pharmaceuticals, Inc. | Chimeric complement inhibitor proteins |
EP0751787B1 (en) | 1994-03-23 | 2005-01-12 | Alexion Pharmaceuticals, Inc. | Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation |
US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
US5679564A (en) | 1994-10-05 | 1997-10-21 | Antex Biologics, Inc. | Methods for producing enhanced antigenic campylobacter bacteria and vaccines |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
JPH11514853A (ja) | 1995-09-08 | 1999-12-21 | ジエンザイム コーポレイション | 遺伝子治療のための改良されたaavベクター |
AU5711196A (en) | 1996-03-14 | 1997-10-01 | Human Genome Sciences, Inc. | Apoptosis inducing molecule i |
CA2248868A1 (en) | 1996-03-22 | 1997-09-25 | Human Genome Sciences, Inc. | Apoptosis inducing molecule ii |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
CA2616914C (en) | 1996-12-03 | 2012-05-29 | Abgenix, Inc. | Egfr-binding antibody |
US20050197285A1 (en) | 1997-03-07 | 2005-09-08 | Rosen Craig A. | Human secreted proteins |
WO2001036432A2 (en) | 1999-11-19 | 2001-05-25 | Human Genome Sciences, Inc. | 18 human secreted proteins |
US6472520B2 (en) | 1997-03-21 | 2002-10-29 | The Trustees Of Columbia University In The City Of New York | Rat PEG-3 promoter |
CZ294425B6 (cs) | 1997-04-14 | 2005-01-12 | Micromet Ag | Způsob výroby anti-humánního antigenového receptoru, anti-humánní antigenový receptor, řetězec VH a VL, souprava pro selekci anti-humánních antigenových receptorů a farmaceutická kompozice, obsahující uvedený receptor |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
CA2302317A1 (en) | 1997-08-26 | 1999-03-04 | Gliatech, Inc. | A process for inhibiting complement activation via the alternative pathway |
US6410708B1 (en) | 1997-11-21 | 2002-06-25 | Genentech, Inc. | Nucleic acids encoding A-33 related antigen polypeptides |
US6642051B1 (en) | 1997-10-21 | 2003-11-04 | Targeted Genetics Corporation | Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors |
EP1042343B1 (en) | 1997-11-03 | 2008-01-23 | Human Genome Sciences, Inc. | Vegi, an inhibitor of angiogenesis and tumor growth |
US6595142B2 (en) | 1997-11-13 | 2003-07-22 | M.C.M. Holding A/S | Floor for a transport means and profiles for the construction thereof as well as a vehicle provided with such a floor |
US8088386B2 (en) * | 1998-03-20 | 2012-01-03 | Genentech, Inc. | Treatment of complement-associated disorders |
US7282565B2 (en) | 1998-03-20 | 2007-10-16 | Genentech, Inc. | PRO362 polypeptides |
US7419663B2 (en) | 1998-03-20 | 2008-09-02 | Genentech, Inc. | Treatment of complement-associated disorders |
EP1481990B1 (en) | 1997-11-21 | 2007-06-06 | Genentech, Inc. | A-33 related antigens and their pharmacological uses |
US8007798B2 (en) * | 1997-11-21 | 2011-08-30 | Genentech, Inc. | Treatment of complement-associated disorders |
US7192589B2 (en) | 1998-09-16 | 2007-03-20 | Genentech, Inc. | Treatment of inflammatory disorders with STIgMA immunoadhesins |
AU2577799A (en) | 1998-02-09 | 1999-08-23 | Human Genome Sciences, Inc. | 45 human secreted proteins |
US7112327B2 (en) | 1998-02-20 | 2006-09-26 | Tanox, Inc. | Inhibition of complement activation |
US6956107B2 (en) | 1998-02-20 | 2005-10-18 | Tanox, Inc. | Inhibitors of complement activation |
BRPI9909220B1 (pt) | 1998-02-20 | 2018-09-18 | Genentech Inc | hibridoma, anticorpo monoclonal, anticorpo humanizado, anticorpo quimérico, anticorpo desimunizado ou fragmento de tais anticorpos |
ES2312205T3 (es) | 1998-03-10 | 2009-02-16 | Genentech, Inc. | Nuevo polipeptido y acidos nucleicos que lo codifican. |
EP1108019A2 (en) | 1998-08-27 | 2001-06-20 | Incyte Pharmaceuticals, Inc. | Protein transport-associated molecules |
EP1141285A2 (en) | 1998-12-16 | 2001-10-10 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
EP1141284A2 (en) | 1998-12-22 | 2001-10-10 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
KR100940380B1 (ko) | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
EP1220905A2 (en) | 1999-03-08 | 2002-07-10 | Genentech Inc. | Composition and methods for the treatment of immune related diseases |
IL145310A0 (en) | 1999-03-11 | 2003-01-12 | Rmf Dictagene Sa | Vascular adhesion molecules and modulation of their function |
US6642353B1 (en) | 1999-03-17 | 2003-11-04 | Chugai Seiyaku Kabushiki Kaisha | Peptide ligands for the erythropoietin receptor |
AU2883900A (en) | 1999-07-07 | 2001-01-30 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
CA2492070A1 (en) | 1999-12-01 | 2001-06-07 | Kevin P. Baker | Lung tumor marker pro4329 polypeptides and nucleic acids encoding the same |
US6821775B1 (en) * | 2000-02-11 | 2004-11-23 | Genvec, Inc. | Viral vector encoding pigment epithelium-derived factor |
WO2001070818A1 (en) | 2000-03-23 | 2001-09-27 | Tanox, Inc. | Anti-c2/c2a inhibitors of complement activation |
EP1287364B1 (en) * | 2000-04-29 | 2008-10-22 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration-related disorders |
CA2412211A1 (en) | 2000-06-23 | 2002-01-03 | Genetech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
JP2004516013A (ja) | 2000-07-20 | 2004-06-03 | ジェネンテック・インコーポレーテッド | 血管形成に関連する障害を診断及び治療するための組成物と方法 |
EP2113516B1 (en) * | 2000-10-10 | 2014-05-21 | Genentech, Inc. | Antibodies against C5 inhibiting type II endothelial cell activation |
WO2002030986A2 (en) | 2000-10-13 | 2002-04-18 | Biogen, Inc. | HUMANIZED ANTI-LT-β-R ANTIBODIES |
US20040077575A1 (en) * | 2002-01-11 | 2004-04-22 | Giordano Giovan Giacomo | Inhibition of pathological angiogenesis in vivo |
US6867189B2 (en) | 2001-07-26 | 2005-03-15 | Genset S.A. | Use of adipsin/complement factor D in the treatment of metabolic related disorders |
ES2283594T5 (es) | 2001-08-17 | 2016-03-15 | Genentech, Inc. | Inhibidores de la ruta del complemento que se unen a C5 y C5a sin impedir la formación de C5b |
TWI323265B (en) | 2002-08-06 | 2010-04-11 | Glaxo Group Ltd | Antibodies |
US20040152105A1 (en) | 2002-09-06 | 2004-08-05 | Cytos Biotechnology Ag. | Immune modulatory compounds and methods |
WO2005025516A2 (en) * | 2003-09-12 | 2005-03-24 | The Regents Of The University Of California | Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregates |
US7816497B2 (en) * | 2002-10-30 | 2010-10-19 | University Of Kentucky | Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration |
CN101897969B (zh) * | 2003-02-21 | 2014-04-02 | 健泰科生物技术公司 | 补体抑制剂在制备用于预防或抑制组织损伤的药物中的用途 |
RU2232991C1 (ru) | 2003-04-09 | 2004-07-20 | Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" | Способ определения функциональной активности фактора d комплемента человека |
US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
WO2005014849A2 (en) | 2003-07-03 | 2005-02-17 | Euro-Celtique, S.A. | Genes associated with responses to neuropathic pain |
WO2005025509A2 (en) | 2003-09-11 | 2005-03-24 | Board Of Regents, The University Of Texas System | Methods and materials for treating autoimmune diseases and conditions |
US20050169921A1 (en) | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
US7794713B2 (en) | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
CN102618644A (zh) | 2004-11-18 | 2012-08-01 | 耶鲁大学 | 治疗眼病的方法和组合物 |
WO2006071856A2 (en) | 2004-12-23 | 2006-07-06 | Glycofi, Inc. | Immunoglobulins comprising predominantly a man5glcnac2 glycoform |
JP2008529536A (ja) * | 2005-02-14 | 2008-08-07 | ユニバーシティー オブ アイオワ リサーチ ファウンデーション | 加齢性黄斑変性を処置および診断するための方法および試薬 |
CN101325963B (zh) * | 2005-10-08 | 2016-01-27 | 博泰迪亚制药公司 | 用于眼部病症的补体抑制素和其类似物 |
KR20170002684A (ko) | 2005-11-04 | 2017-01-06 | 제넨테크, 인크. | 안질환 치료를 위한 보체 경로 억제제의 용도 |
US20070190057A1 (en) | 2006-01-23 | 2007-08-16 | Jian Wu | Methods for modulating mannose content of recombinant proteins |
PE20121034A1 (es) | 2006-11-02 | 2012-08-25 | Genentech Inc | Anticuerpos anti-factor d humanizados |
AR066660A1 (es) | 2007-05-23 | 2009-09-02 | Genentech Inc | Prevencion y tratamiento de condiciones del ojo asociadas con su complemento |
CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
-
2006
- 2006-11-04 KR KR1020167036246A patent/KR20170002684A/ko not_active Application Discontinuation
- 2006-11-04 ZA ZA200803659A patent/ZA200803659B/xx unknown
- 2006-11-04 BR BRPI0619657-8A patent/BRPI0619657A2/pt not_active IP Right Cessation
- 2006-11-04 CN CN201711120837.XA patent/CN107929731A/zh active Pending
- 2006-11-04 DK DK12172001.5T patent/DK2500030T4/en active
- 2006-11-04 CA CA2624393A patent/CA2624393C/en not_active Expired - Fee Related
- 2006-11-04 NZ NZ567483A patent/NZ567483A/en not_active IP Right Cessation
- 2006-11-04 HU HUE12172001A patent/HUE026423T2/en unknown
- 2006-11-04 MY MYPI20081426 patent/MY151064A/en unknown
- 2006-11-04 EP EP12172001.5A patent/EP2500030B2/en active Active
- 2006-11-04 CN CNA2006800504810A patent/CN101355956A/zh active Pending
- 2006-11-04 KR KR1020197006092A patent/KR20190026048A/ko not_active Application Discontinuation
- 2006-11-04 MX MX2011003503A patent/MX337061B/es unknown
- 2006-11-04 WO PCT/US2006/043103 patent/WO2007056227A2/en active Application Filing
- 2006-11-04 CA CA2903896A patent/CA2903896A1/en not_active Abandoned
- 2006-11-04 PT PT121720015T patent/PT2500030E/pt unknown
- 2006-11-04 AU AU2006311803A patent/AU2006311803C1/en not_active Ceased
- 2006-11-04 KR KR1020177037729A patent/KR20180002911A/ko not_active Application Discontinuation
- 2006-11-04 RU RU2008122341/15A patent/RU2417099C2/ru not_active IP Right Cessation
- 2006-11-04 KR KR1020137030524A patent/KR20130137716A/ko not_active Application Discontinuation
- 2006-11-04 KR KR1020087013385A patent/KR101511787B1/ko active IP Right Grant
- 2006-11-04 KR KR1020157011618A patent/KR20150055628A/ko not_active Application Discontinuation
- 2006-11-04 PL PL12172001T patent/PL2500030T5/pl unknown
- 2006-11-04 SG SG10201804008UA patent/SG10201804008UA/en unknown
- 2006-11-04 EP EP17186993.6A patent/EP3299027A1/en not_active Withdrawn
- 2006-11-04 EP EP15172358.2A patent/EP2998318A1/en not_active Withdrawn
- 2006-11-04 MX MX2016001813A patent/MX360959B/es unknown
- 2006-11-04 SI SI200631974T patent/SI2500030T2/sl unknown
- 2006-11-04 JP JP2008539095A patent/JP2009514888A/ja not_active Withdrawn
- 2006-11-04 US US12/092,346 patent/US8753625B2/en not_active Expired - Fee Related
- 2006-11-04 NZ NZ594285A patent/NZ594285A/xx not_active IP Right Cessation
- 2006-11-04 ES ES12172001.5T patent/ES2551202T5/es active Active
- 2006-11-04 UA UAA200807619A patent/UA99591C2/ru unknown
- 2006-11-04 EP EP06836941A patent/EP1942922A4/en not_active Withdrawn
-
2008
- 2008-04-01 IL IL190547A patent/IL190547A/en not_active IP Right Cessation
- 2008-04-30 MX MX2018014357A patent/MX2018014357A/es unknown
- 2008-05-03 CR CR10041A patent/CR10041A/es unknown
- 2008-05-30 MA MA30972A patent/MA29976B1/fr unknown
- 2008-06-03 NO NO20082483A patent/NO20082483L/no not_active Application Discontinuation
- 2008-06-04 EC EC2008008500A patent/ECSP088500A/es unknown
-
2009
- 2009-09-04 JP JP2009205369A patent/JP2009280626A/ja active Pending
-
2010
- 2010-12-21 RU RU2010152367/15A patent/RU2583927C2/ru not_active IP Right Cessation
-
2012
- 2012-12-10 JP JP2012269482A patent/JP2013049724A/ja not_active Withdrawn
-
2013
- 2013-01-24 ZA ZA2013/00649A patent/ZA201300649B/en unknown
- 2013-03-14 HK HK13103212.1A patent/HK1175718A1/zh not_active IP Right Cessation
- 2013-06-17 PH PH12013501270A patent/PH12013501270B1/en unknown
-
2014
- 2014-05-06 US US14/270,848 patent/US20140335078A1/en not_active Abandoned
-
2015
- 2015-01-29 JP JP2015015014A patent/JP2015083609A/ja not_active Withdrawn
- 2015-06-08 JP JP2015115473A patent/JP2015157862A/ja active Pending
-
2016
- 2016-09-23 HK HK16111213.0A patent/HK1223106A1/zh unknown
-
2017
- 2017-02-20 JP JP2017028964A patent/JP2017095522A/ja not_active Withdrawn
- 2017-02-26 IL IL250772A patent/IL250772A0/en unknown
- 2017-12-15 US US15/844,391 patent/US20180334495A1/en not_active Abandoned
-
2018
- 2018-11-22 IL IL263237A patent/IL263237A/en unknown
- 2018-12-21 JP JP2018238998A patent/JP2019043963A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12013501270A1 (en) | Use of complement pathway inhibitors to treat ocular diseases | |
WO2010126626A3 (en) | Dual mechanism inhibitors for the treatment of disease | |
EA201791168A1 (ru) | Способы и составы для лечения сосудистых заболеваний глаз | |
MX2018013003A (es) | Oligonucleotidos para tratar una enfermedad ocular. | |
CY1110435T1 (el) | Μεθοδοι και συνθεσεις για τη θεραπεια οφθαλμικων καταστασεων με παραγωγα ρετινολης | |
BR112015018438A2 (pt) | anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento | |
MX351152B (es) | Compstatina y analogos de la misma para tratar trastornos oculares. | |
BR112016000546A2 (pt) | métodos para tratar ou prevenir condições oftalmológicas | |
CO6341486A2 (es) | Tratamiento y profilaxis de amiloidosis | |
BRPI0606172A2 (pt) | métodos e composições para o tratamento de distúrbios oculares | |
EA201492031A1 (ru) | Способы лечения диабетической ретинопатии и других офтальмологических заболеваний | |
ATE445415T1 (de) | Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung | |
AR055810A1 (es) | Uso de inhibidores de acetilcolinesterasa e inhibidores de la produccion de beta-app o acumulacion de a-beta | |
MY153669A (en) | Ocular allergy treatments field of the invention | |
EA200800291A1 (ru) | Способы и композиции для лечения офтальмологических состояний | |
WO2007046083A3 (en) | Compositions for treatment of eye diseases | |
WO2007098122A3 (en) | Methods for the treatment of macular degeneration and related eye conditions | |
AR067395A1 (es) | Inhibicion de htra1 mediada por iarn para el tratamiento de la degeneracion macular | |
MX2019009586A (es) | Composiciones y metodos para tratar enfermedades asociadas con la permeabilidad del epitelio intestinal. | |
WO2007053807A3 (en) | Calcitriol for treating intraocular diseases associated with angiogenesis | |
MX2021004755A (es) | Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria. | |
NZ772236A (en) | Pharmaceutical combination for use in age-related and/or degenerative diseases | |
EA200800338A1 (ru) | Профилактика и лечение офтальмологических осложнений диабета | |
WO2008048675A3 (en) | Treatment for age-related macular degeneration and other diseases of the eye | |
PH12017502145A1 (en) | Composition and uses thereof |